During the first meeting of FDA’s Patient Engagement Advisory Committee (PEAC) on Wednesday (Oct. 11), patients and patient advocates, industry, and FDA discussed a need to craft regulatory policy around patient engagement in clinical trials and provided solutions for increasing and possibly incentivizing patient participation and retention in studies. Researchers called on FDA to implement regulations around patient engagement that would possibly help companies move toward more patient-centered drug development. And throughout the meeting, which featured roundtable discussions moderated by...